CD8A and neoplasm: Among patients with a high TLR5 expression, five-year DSS was 81.8% (95% CI 65.7–97.9) among those with a CD3–CD8 tumor–stroma index of 4, falling to 50.3% (95% CI 31.9–68.7; p < 0.001, log-rank test; Fig 3f) among patients with the lowest CD3–CD8 tumor–stroma index.